S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Massive "Lightning Line" Rollout Underway Across America… (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
NASDAQ:ALLK

Allakos (ALLK) Stock Price, News & Analysis

$1.29
+0.07 (+5.74%)
(As of 02/21/2024 ET)
Today's Range
$1.22
$1.30
50-Day Range
$1.02
$3.23
52-Week Range
$1.00
$6.74
Volume
565,737 shs
Average Volume
2.15 million shs
Market Capitalization
$112.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.42

Allakos MarketRank™ Stock Analysis

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
630.0% Upside
$9.42 Price Target
Short Interest
Bearish
5.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.00mentions of Allakos in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.94) to ($1.52) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.57 out of 5 stars

Medical Sector

75th out of 932 stocks

Pharmaceutical Preparations Industry

25th out of 429 stocks


ALLK stock logo

About Allakos Stock (NASDAQ:ALLK)

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.

ALLK Stock Price History

ALLK Stock News Headlines

ALLK Sep 2024 2.000 call
ALLK Sep 2024 2.500 call
Disturbing Truth About Biden's New Program To Seize Your Cash
A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
ALLK Mar 2024 1.500 call
Disturbing Truth About Biden's New Program To Seize Your Cash
A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Allakos price target lowered by 50c at Barclays, here's why
Allakos just downgraded at Cantor Fitzgerald, here's why
Allakos just downgraded at LifeSci Capital, here's why
Why Is Allakos (ALLK) Stock Down 57% Today?
Allakos crashes on restructuring plans
William Blair Upgrades Allakos (ALLK)
Allakos assumed with a Buy at Jefferies
See More Headlines
Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2023
Today
2/22/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALLK
Fax
N/A
Employees
123
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.42
High Stock Price Target
$22.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+630.0%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$-319,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.64 per share

Miscellaneous

Free Float
62,921,000
Market Cap
$112.85 million
Optionable
Optionable
Beta
0.80
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Robert Alexander Ph.D. (Age 54)
    CEO & Director
    Comp: $1.46M
  • Dr. Adam L. Tomasi Ph.D. (Age 54)
    President
    Comp: $1.11M
  • Mr. Baird Radford III (Age 54)
    Chief Financial Officer
    Comp: $708.26k
  • Ms. Mary Cromwell Ph.D.
    Chief Technical Officer
  • Dr. Chin Lee M.D. (Age 53)
    M.P.H., Chief Medical Officer
  • Mr. Alan Chang
    Director of Medical Affairs & Data Analytics














ALLK Stock Analysis - Frequently Asked Questions

Should I buy or sell Allakos stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View ALLK analyst ratings
or view top-rated stocks.

What is Allakos' stock price target for 2024?

7 equities research analysts have issued 1 year price objectives for Allakos' shares. Their ALLK share price targets range from $1.00 to $22.00. On average, they predict the company's stock price to reach $9.42 in the next twelve months. This suggests a possible upside of 630.0% from the stock's current price.
View analysts price targets for ALLK
or view top-rated stocks among Wall Street analysts.

How have ALLK shares performed in 2024?

Allakos' stock was trading at $2.73 on January 1st, 2024. Since then, ALLK stock has decreased by 52.7% and is now trading at $1.29.
View the best growth stocks for 2024 here
.

When is Allakos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our ALLK earnings forecast
.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) announced its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.49) EPS for the quarter, meeting the consensus estimate of ($0.49).

What ETF holds Allakos' stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 22,191 shares of ALLK stock, representing 1.04% of its portfolio.

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

When did Allakos IPO?

(ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

Who are Allakos' major shareholders?

Allakos' stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (9.05%), Price T Rowe Associates Inc. MD (9.05%), Vanguard Group Inc. (3.72%), Vontobel Holding Ltd. (0.86%), Sectoral Asset Management Inc. (0.86%) and Northern Trust Corp (0.65%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends
.

How do I buy shares of Allakos?

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALLK) was last updated on 2/22/2024 by MarketBeat.com Staff